These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 30771488)
21. Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB. Kim WS; Kim HJ; Lee ZH; Lee Y; Kim HH Exp Cell Res; 2013 Feb; 319(4):436-46. PubMed ID: 23246654 [TBL] [Abstract][Full Text] [Related]
22. Zscan10 is dispensable for maintenance of pluripotency in mouse embryonic stem cells. Yamane M; Fujii S; Ohtsuka S; Niwa H Biochem Biophys Res Commun; 2015 Dec; 468(4):826-31. PubMed ID: 26592664 [TBL] [Abstract][Full Text] [Related]
24. WSS25, a sulfated polysaccharide, inhibits RANKL-induced mouse osteoclast formation by blocking SMAD/ID1 signaling. Chen C; Qin Y; Fang JP; Ni XY; Yao J; Wang HY; Ding K Acta Pharmacol Sin; 2015 Sep; 36(9):1053-64. PubMed ID: 26299951 [TBL] [Abstract][Full Text] [Related]
25. LncRNA-Jak3:Jak3 coexpressed pattern regulates monosodium urate crystal-induced osteoclast differentiation through Nfatc1/Ctsk expression. Lee CP; Huang YN; Nithiyanantham S; Huang CM; Ko YC Environ Toxicol; 2019 Feb; 34(2):179-187. PubMed ID: 30387921 [TBL] [Abstract][Full Text] [Related]
26. GATA4 represses RANKL in osteoblasts via multiple long-range enhancers to regulate osteoclast differentiation. Khalid AB; Slayden AV; Kumpati J; Perry CD; Berryhill SB; Crawford JA; Fatima I; Morselli M; Pellegrini M; Miranda-Carboni GA; Krum SA Bone; 2018 Nov; 116():78-86. PubMed ID: 30031905 [TBL] [Abstract][Full Text] [Related]
27. Constant hypoxia inhibits osteoclast differentiation and bone resorption by regulating phosphorylation of JNK and IκBα. Ma Z; Yu R; Zhao J; Sun L; Jian L; Li C; Liu X Inflamm Res; 2019 Feb; 68(2):157-166. PubMed ID: 30604211 [TBL] [Abstract][Full Text] [Related]
28. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis. Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732 [TBL] [Abstract][Full Text] [Related]
29. The transcription factor FBI-1/OCZF/LRF is expressed in osteoclasts and regulates RANKL-induced osteoclast formation in vitro and in vivo. Kukita A; Kukita T; Nagata K; Teramachi J; Li YJ; Yoshida H; Miyamoto H; Gay S; Pessler F; Shobuike T Arthritis Rheum; 2011 Sep; 63(9):2744-54. PubMed ID: 21590684 [TBL] [Abstract][Full Text] [Related]
30. RNA-binding protein Musashi2 induced by RANKL is critical for osteoclast survival. Fujiwara T; Zhou J; Ye S; Zhao H Cell Death Dis; 2016 Jul; 7(7):e2300. PubMed ID: 27441652 [TBL] [Abstract][Full Text] [Related]
31. STAT5 is a key transcription factor for IL-3-mediated inhibition of RANKL-induced osteoclastogenesis. Lee J; Seong S; Kim JH; Kim K; Kim I; Jeong BC; Nam KI; Kim KK; Hennighausen L; Kim N Sci Rep; 2016 Aug; 6():30977. PubMed ID: 27485735 [TBL] [Abstract][Full Text] [Related]
32. Aconine inhibits RANKL-induced osteoclast differentiation in RAW264.7 cells by suppressing NF-κB and NFATc1 activation and DC-STAMP expression. Zeng XZ; He LG; Wang S; Wang K; Zhang YY; Tao L; Li XJ; Liu SW Acta Pharmacol Sin; 2016 Feb; 37(2):255-63. PubMed ID: 26592521 [TBL] [Abstract][Full Text] [Related]
33. MiR-7b directly targets DC-STAMP causing suppression of NFATc1 and c-Fos signaling during osteoclast fusion and differentiation. Dou C; Zhang C; Kang F; Yang X; Jiang H; Bai Y; Xiang J; Xu J; Dong S Biochim Biophys Acta; 2014 Nov; 1839(11):1084-96. PubMed ID: 25123438 [TBL] [Abstract][Full Text] [Related]
34. Coenzyme q10 regulates osteoclast and osteoblast differentiation. Moon HJ; Ko WK; Jung MS; Kim JH; Lee WJ; Park KS; Heo JK; Bang JB; Kwon IK J Food Sci; 2013 May; 78(5):H785-891. PubMed ID: 23582186 [TBL] [Abstract][Full Text] [Related]
35. Protocatechuic acid inhibits osteoclast differentiation and stimulates apoptosis in mature osteoclasts. Wu YX; Wu TY; Xu BB; Xu XY; Chen HG; Li XY; Wang G Biomed Pharmacother; 2016 Aug; 82():399-405. PubMed ID: 27470378 [TBL] [Abstract][Full Text] [Related]
36. Early growth response 2 negatively modulates osteoclast differentiation through upregulation of Id helix-loop-helix proteins. Kim HJ; Hong JM; Yoon KA; Kim N; Cho DW; Choi JY; Lee IK; Kim SY Bone; 2012 Oct; 51(4):643-50. PubMed ID: 22842221 [TBL] [Abstract][Full Text] [Related]
37. Calcitonin inhibits osteoclast formation in mouse haematopoetic cells independently of transcriptional regulation by receptor activator of NF-{kappa}B and c-Fms. Granholm S; Lundberg P; Lerner UH J Endocrinol; 2007 Dec; 195(3):415-27. PubMed ID: 18000304 [TBL] [Abstract][Full Text] [Related]
38. Roles of Enhancer RNAs in RANKL-induced Osteoclast Differentiation Identified by Genome-wide Cap-analysis of Gene Expression using CRISPR/Cas9. Sakaguchi Y; Nishikawa K; Seno S; Matsuda H; Takayanagi H; Ishii M Sci Rep; 2018 May; 8(1):7504. PubMed ID: 29760402 [TBL] [Abstract][Full Text] [Related]
39. Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways. Gan K; Yang L; Xu L; Feng X; Zhang Q; Wang F; Tan W; Zhang M Int Immunopharmacol; 2016 Jun; 35():294-300. PubMed ID: 27085680 [TBL] [Abstract][Full Text] [Related]
40. Herbacetin inhibits RANKL-mediated osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo. Li L; Sapkota M; Kim SW; Soh Y Eur J Pharmacol; 2016 Apr; 777():17-25. PubMed ID: 26923730 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]